Stock Traders Purchase Large Volume of Pieris Pharmaceuticals Call Options (NASDAQ:PIRS)

Share on StockTwits

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) saw unusually large options trading on Thursday. Investors acquired 4,207 call options on the stock. This is an increase of approximately 2,993% compared to the average volume of 136 call options.

In other news, major shareholder Bvf Partners L. P/Il sold 50,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $4.50, for a total transaction of $225,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.59% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Parametric Portfolio Associates LLC raised its position in Pieris Pharmaceuticals by 25.4% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 21,177 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 4,290 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Pieris Pharmaceuticals by 1,074.8% during the second quarter. Tower Research Capital LLC TRC now owns 5,874 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 5,374 shares during the last quarter. Strs Ohio raised its position in shares of Pieris Pharmaceuticals by 7.5% during the second quarter. Strs Ohio now owns 112,900 shares of the biotechnology company’s stock worth $530,000 after acquiring an additional 7,900 shares during the last quarter. Lindbrook Capital LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $37,000. Finally, Clear Harbor Asset Management LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth $47,000. Hedge funds and other institutional investors own 55.11% of the company’s stock.

Several brokerages have recently weighed in on PIRS. Zacks Investment Research raised Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 26th. Robert W. Baird lowered Pieris Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 price objective on the stock. in a report on Tuesday, July 30th. ValuEngine lowered Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Pieris Pharmaceuticals in a research note on Friday, September 27th. Finally, William Blair reaffirmed a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Friday, September 27th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $5.67.

PIRS stock traded up $0.16 during trading on Friday, hitting $3.28. The company had a trading volume of 477,331 shares, compared to its average volume of 1,105,532. The company has a fifty day moving average price of $4.43 and a two-hundred day moving average price of $4.18. Pieris Pharmaceuticals has a fifty-two week low of $2.39 and a fifty-two week high of $6.04. The company has a market cap of $148.18 million, a P/E ratio of -6.56 and a beta of 1.27.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings data on Friday, August 9th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03). Pieris Pharmaceuticals had a negative net margin of 147.19% and a negative return on equity of 114.25%. The business had revenue of $5.33 million during the quarter, compared to the consensus estimate of $7.32 million. As a group, analysts expect that Pieris Pharmaceuticals will post -0.91 earnings per share for the current year.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Story: Stock Portfolio Tracker

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.